Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
Dana-Farber Cancer Institute, Boston, MA, United States; Harvard School of Public Health, Boston, MA, United States.
Leuk Res. 2014 Aug;38(8):901-6. doi: 10.1016/j.leukres.2014.05.018. Epub 2014 Jun 2.
We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥ 3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.
我们研究了在东部肿瘤协作组试验中达到完全缓解 1 期（CR1）的 1229 名年轻急性髓系白血病患者。我们将晚期复发定义为在 CR1 后≥3 年发生。中位随访时间为 11.3 年，有 14 例晚期复发（CR1 患者的 1.1%；3 年 CR1 患者的 3.3%）。8 例患者获得第二次完全缓解，晚期复发后的中位总生存期为 3.2 年。大多数接受检测的患者（11 例中的 9 例）在诊断时核型正常；复发时无新的细胞遗传学异常。晚期复发较为罕见，几乎所有 3 年 CR1 患者都被治愈。如果发生晚期复发，结局相对较好。
